News Daily News Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies Michael O'Riordan December 19, 2023
News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Conference News EAS 2023 Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH Michael O'Riordan May 26, 2023
News Conference News EAS 2023 High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture Michael O'Riordan May 23, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies Todd Neale July 14, 2022
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Daily News Homozygous FH Diagnosis Often Comes Late, With Lackluster Care Michael O'Riordan February 10, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Daily News Cumulative Burden of LDL Cholesterol Increases CHD Risk Michael O'Riordan September 23, 2021
News Daily News Heterozygous FH Diagnosed Late, Remains Undertreated Michael O'Riordan September 13, 2021
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021